“Scientific data regarding Codivir’s mechanism of action strongly suggest that Codivir is effective against mutations of the Covid virus, including the recently discovered Omicron variant”, said Zyon Ayni, CEO and Founder of Code Pharma on Yahoo Finance. The article’s title is “COVID-19 drug developer Code Pharma announces limited fundraising round for international professional investors and plans for IPO”.
Ayni added: “Even before the results of the phase II study, we have received emergency approvals and orders for production. Therefore, we are not only facing exceptionally strong commercial potential, but potentially a breakthrough in the field of antiviral therapy, not only for COVID-19 patients, but also for diseases such as influenza and other RNA viruses.”
